Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLY NYSE:BVS NASDAQ:SIBN NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$2.51-2.1%$1.67$1.32▼$4.98$644.46M2.596.55 million shs10.15 million shsBVSBioventus$6.65-2.1%$7.02$5.81▼$14.38$561.39M0.81388,734 shs237,970 shsSIBNSiBone$15.33+5.8%$15.65$11.70▼$20.05$625.11M0.83432,021 shs729,048 shsSTIMNeuronetics$2.91+2.8%$3.36$0.52▼$5.92$187.13M1.171.27 million shs666,954 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-2.34%+29.46%+61.09%+29.46%+34.32%BVSBioventus-2.06%-0.60%-7.51%-9.15%-40.57%SIBNSiBone+5.80%+4.14%-5.89%-16.87%+15.79%STIMNeuronetics+2.83%+6.59%-9.91%-16.86%+263.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$2.51-2.1%$1.67$1.32▼$4.98$644.46M2.596.55 million shs10.15 million shsBVSBioventus$6.65-2.1%$7.02$5.81▼$14.38$561.39M0.81388,734 shs237,970 shsSIBNSiBone$15.33+5.8%$15.65$11.70▼$20.05$625.11M0.83432,021 shs729,048 shsSTIMNeuronetics$2.91+2.8%$3.36$0.52▼$5.92$187.13M1.171.27 million shs666,954 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-2.34%+29.46%+61.09%+29.46%+34.32%BVSBioventus-2.06%-0.60%-7.51%-9.15%-40.57%SIBNSiBone+5.80%+4.14%-5.89%-16.87%+15.79%STIMNeuronetics+2.83%+6.59%-9.91%-16.86%+263.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 2.40Hold$3.0019.76% UpsideBVSBioventus 2.75Moderate Buy$13.75106.77% UpsideSIBNSiBone 2.50Moderate Buy$23.6754.38% UpsideSTIMNeuronetics 2.00Hold$7.00140.55% UpsideCurrent Analyst Ratings BreakdownLatest STIM, SIBN, BFLY, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025BFLYButterfly NetworkWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SIBNSiBoneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025STIMNeuroneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/6/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.008/4/2025BFLYButterfly NetworkCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive$2.008/1/2025BFLYButterfly NetworkOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$82.06M7.68N/AN/A$0.79 per share3.17BVSBioventus$564.14M0.97$0.53 per share12.58$2.80 per share2.38SIBNSiBone$167.18M3.96N/AN/A$3.98 per share3.85STIMNeuronetics$74.89M2.57N/AN/A$0.57 per share5.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$72.49M-$0.28N/AN/AN/A-71.79%-30.53%-21.80%11/7/2025 (Estimated)BVSBioventus-$156.23MN/AN/A14.46N/A-7.11%15.61%4.01%N/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)STIMNeuronetics-$43.71M-$1.13N/AN/AN/A-43.47%-156.36%-35.69%11/11/2025 (Estimated)Latest STIM, SIBN, BFLY, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025STIMNeuronetics-$0.08-$0.15-$0.07-$0.15$36.80 million$38.11 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million8/1/2025Q2 2025BFLYButterfly Network-$0.07-$0.06+$0.01-$0.06$23.91 million$23.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A5.684.14BVSBioventus1.851.410.99SIBNSiBone0.218.387.00STIMNeuronetics1.762.021.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%BVSBioventus62.94%SIBNSiBone98.11%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%BVSBioventus33.00%SIBNSiBone3.90%STIMNeuronetics9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460251.74 million188.35 millionOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableSIBNSiBone35043.14 million41.46 millionOptionableSTIMNeuronetics18066.12 million59.65 millionOptionableSTIM, SIBN, BFLY, and BVS HeadlinesRecent News About These CompaniesNeuronetics management to meet virtually with Piper SandlerSeptember 23, 2025 | msn.comNeuronetics Gains Breakthrough as New York Medicaid Expands Coverage for TMS Depression TherapySeptember 20, 2025 | msn.comNeuronetics, Inc.'s (NASDAQ:STIM) last week's 25% decline must have disappointed individual investors who have a significant stakeSeptember 17, 2025 | finance.yahoo.comNew York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)September 17, 2025 | globenewswire.comCubist Systematic Strategies LLC Acquires New Stake in Neuronetics, Inc. $STIMSeptember 10, 2025 | marketbeat.comUnusually active option classes on open September 9thSeptember 9, 2025 | msn.comNeuronetics, Inc. (STIM) Positions as Neurohealth Leader with Adolescent BreakthroughSeptember 2, 2025 | finance.yahoo.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 6, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comNeuronetics, Inc. (STIM) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comNeuronetics Reports Second Quarter 2025 Financial and Operating ResultsAugust 5, 2025 | manilatimes.netMWhat To Expect From Neuronetics Inc (STIM) Q2 2025 EarningsAugust 5, 2025 | finance.yahoo.comNeuronetics (STIM) Reports Q2 Loss, Tops Revenue EstimatesAugust 5, 2025 | zacks.comNeuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 4, 2025 | globenewswire.comNeuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMSAugust 2, 2025 | msn.comNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsJuly 30, 2025 | globenewswire.comNeuronetics taps local industry veteran as new CFOJuly 15, 2025 | bizjournals.comNeuronetics Names Pfanstiel as CFO to Succeed FurlongJuly 15, 2025 | marketwatch.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | finance.yahoo.comNeuronetics names Steven Pfanstiel chief financial officerJuly 15, 2025 | massdevice.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTIM, SIBN, BFLY, and BVS Company DescriptionsButterfly Network NYSE:BFLY$2.50 -0.06 (-2.15%) Closing price 10/7/2025 03:59 PM EasternExtended Trading$2.52 +0.01 (+0.40%) As of 10/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.Bioventus NYSE:BVS$6.65 -0.14 (-2.06%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$6.64 -0.02 (-0.23%) As of 10/7/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.SiBone NASDAQ:SIBN$15.33 +0.84 (+5.80%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$15.16 -0.17 (-1.11%) As of 10/7/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Neuronetics NASDAQ:STIM$2.91 +0.08 (+2.83%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.91 0.00 (0.00%) As of 10/7/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
